Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis.
Lecomte S, Devreux J, de Streel G, van Baren N, Havelange V, Schröder D, Vaherto N, Vanhaver C, Vanderaa C, Dupuis N, Pecquet C, Coulie PG, Constantinescu SN, Lucas S. Lecomte S, et al. Among authors: havelange v. Blood. 2023 Feb 2;141(5):490-502. doi: 10.1182/blood.2022017097. Blood. 2023. PMID: 36322928 Free PMC article.
MicroRNAs: new players in acute myeloid leukaemia.
Havelange V, Garzon R, Croce CM. Havelange V, et al. Br J Cancer. 2009 Sep 1;101(5):743-8. doi: 10.1038/sj.bjc.6605232. Epub 2009 Aug 11. Br J Cancer. 2009. PMID: 19672257 Free PMC article. Review.
Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium.
Devos T, Verhoef G, Steel E, Mazure D, Lewalle P, Bron D, Berneman Z, Benghiat FS, Mineur P, Theunissen K, Zachée P, Doyen C, Put N, Lejeune M, Van Eygen K, Havelange V, Reusens M, Pluymers W, Peeters K. Devos T, et al. Among authors: havelange v. Acta Haematol. 2019;142(4):197-207. doi: 10.1159/000499329. Epub 2019 Jun 4. Acta Haematol. 2019. PMID: 31163431 Free article. Clinical Trial.
Implications of the miR-10 family in chemotherapy response of NPM1-mutated AML.
Havelange V, Ranganathan P, Geyer S, Nicolet D, Huang X, Yu X, Volinia S, Kornblau SM, Andreeff M, Croce CM, Marcucci G, Bloomfield CD, Garzon R. Havelange V, et al. Blood. 2014 Apr 10;123(15):2412-5. doi: 10.1182/blood-2013-10-532374. Epub 2014 Mar 4. Blood. 2014. PMID: 24596420 Free PMC article.
Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC. Gökbuget N, et al. Among authors: havelange v. Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22. Blood. 2018. PMID: 29358182 Free PMC article. Clinical Trial.
Cooccurring JAK2 V617F and R1063H mutations increase JAK2 signaling and neutrophilia in myeloproliferative neoplasms.
Mambet C, Babosova O, Defour JP, Leroy E, Necula L, Stanca O, Tatic A, Berbec N, Coriu D, Belickova M, Kralova B, Lanikova L, Vesela J, Pecquet C, Saussoy P, Havelange V, Diaconu CC, Divoky V, Constantinescu SN. Mambet C, et al. Among authors: havelange v. Blood. 2018 Dec 20;132(25):2695-2699. doi: 10.1182/blood-2018-04-843060. Epub 2018 Oct 30. Blood. 2018. PMID: 30377194 Free article. No abstract available.
Targets in MPNs and potential therapeutics.
Levy G, Mambet C, Pecquet C, Bailly S, Havelange V, Diaconu CC, Constantinescu SN. Levy G, et al. Among authors: havelange v. Int Rev Cell Mol Biol. 2022;366:41-81. doi: 10.1016/bs.ircmb.2021.06.004. Epub 2021 Sep 23. Int Rev Cell Mol Biol. 2022. PMID: 35153006
The 2 faces of ERK2 in MPNs.
Havelange V, Constantinescu SN. Havelange V, et al. Blood. 2022 Jul 28;140(4):298-300. doi: 10.1182/blood.2022016536. Blood. 2022. PMID: 35900786 Free article. No abstract available.
49 results